BRCA1 and cancer: Larger feasibility studies should consider anti-progestin use or Mifepristone for its potential role in BRCA1 mutation carriers, as part of individualized chemoprevention, given its beneficial experimental effects in HGSOC and cancer field defects in normal human breast tissue [13,14].